• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

    2/13/24 4:59:02 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email
    SC 13G/A 1 tv0323-arcturustherapeuticsh.htm SCHEDULE 13G/A arcturustherapeuticsholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Arcturus Therapeutics Holdings Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  03969T109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  03969T109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    18,233

    7.  SOLE DISPOSITIVE POWER

    1,419,029

    8.  SHARED DISPOSITIVE POWER

    39,351

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,458,380

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.46%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Arcturus Therapeutics Holdings Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    10628 Science Center Drive, Suite 250
    San Diego, CA 92121

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    03969T109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ARCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    5/28/2025$32.00Sector Outperform
    Scotiabank
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    12/13/2023$90.00Buy
    Canaccord Genuity
    7/24/2023$71.00Outperform
    William Blair
    5/11/2023$19.00 → $51.00Neutral → Buy
    H.C. Wainwright
    11/14/2022$35.00Overweight
    Wells Fargo
    11/10/2022$18.00Neutral → Underperform
    Robert W. Baird
    More analyst ratings

    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcturus Therapeutics to Attend Upcoming Investor Conferences

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Jefferies Global Healthcare Conference (Presentation) Wednesday, June 4, 2025 (4:20 p.m. ET) Goldman Sachs Annual Global Healthcare Conference (Fireside Chat) Monday, June 9, 2025 (3:20 p.m. ET) About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vacc

      5/29/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

      Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight

      5/12/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

      2/4/25 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

      Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

      6/20/24 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Appoints John Markels, Ph.D. to its Board of Directors

      Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

      12/13/22 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Arcturus Therapeutics Holdings Inc.

      10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      5/12/25 4:11:34 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      5/12/25 4:05:47 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      5/12/25 2:10:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Arcturus Therapeutics with a new price target

      Scotiabank initiated coverage of Arcturus Therapeutics with a rating of Sector Outperform and set a new price target of $32.00

      5/28/25 8:57:14 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Arcturus Therapeutics with a new price target

      BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00

      1/28/25 8:51:42 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Arcturus Therapeutics with a new price target

      Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00

      8/12/24 7:16:41 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Financials

    Live finance-specific insights

    See more
    • Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

      Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight

      5/12/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

      Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat

      3/6/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Kurata Lance

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:07:29 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Payne Joseph E

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:59 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer & COO Chivukula Pad

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:26 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/8/24 3:17:24 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/5/24 6:07:26 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/5/24 12:18:33 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care